#th Annual Interscience

Related by string. * #th [003] . #th [005] . #th [004] . #TH [001] : #th Fighter Wing . AUGUST #TH SHOW SO . #th Infantry Division . #th Anniversary Edition / annuals . Annuals . annual . ANNUAL : Annual Screen Actors . MOST RECENTLY FILED ANNUAL . Annual Shareholder Meeting . Annual Grammy Awards / : via Wiley InterScience . th Annual Interscience . Wiley InterScience . th Interscience Conference * *

Related by context. All words. (Click for frequent words.) 78 AACR NCI EORTC 75 #th Interscience Conference 73 Chemotherapy ICAAC 73 Antimicrobial Agents 72 ICAAC IDSA 71 Late Breaker 71 ICAAC 71 ECCMID 70 AACR San Antonio 70 #nd EORTC NCI 70 SABCS 69 Gastrointestinal Cancers Symposium 69 evaluating tivozanib 68 AACR EORTC NCI 68 ORAL Sync 68 CROI 68 radezolid 68 ongoing Phase 1b 68 ASH Annual Meeting 67 EORTC NCI AACR 67 Opportunistic Infections CROI 67 ASCO Annual Meeting 67 Molecular Targets 67 ADA Scientific Sessions 67 delafloxacin 67 Genitourinary Cancers Symposium 67 AASLD 67 virus HCV protease inhibitor 67 Canaccord Adams Hepatitis C 67 ECTRIMS 66 nd Annual Meeting 66 EORTC NCI AACR Symposium 66 NASDAQ CYTK announced 66 AACR #st Annual Meeting 66 #rd Annual CTRC 66 FOLOTYN ® 66 ASCO Genitourinary Cancers Symposium 66 Retroviruses 65 Clinical Oncology Annual Meeting 65 ASCO GI 65 Hematology ASH Annual Meeting 65 st Annual Meeting 65 Rheumatology Annual 65 Phase Ib clinical 65 liposome injection 65 EASL 65 Clinical Oncology ASCO Annual 65 AASLD Meeting 65 oral prodrug 65 BiTE R 65 entitled Synergistic 65 ASCO GU 65 preclinical efficacy 65 non nucleoside inhibitor 65 Phase 1b trial 64 Digestive Disease Week 64 ON #.Na 64 BARACLUDE ® 64 Preclinical Data 64 Hsp# Inhibitor 64 BRIM3 64 Arteriosclerosis Thrombosis 64 CTRC AACR San Antonio 64 Rheumatology ACR Annual 64 Hematology Annual Meeting 64 Transcatheter Cardiovascular Therapeutics TCT 64 fosbretabulin 64 Society CTOS 64 Annual Scientific Sessions 64 Edge STudy 64 lucinactant 64 LymphoStat B TM 64 KRN# 64 Preclinical Study 64 Combination REOLYSIN R 64 Cancers Symposium 64 Biological Therapy 64 teriflunomide 63 BARACLUDE R 63 Digestive Disease Week DDW 63 Interscience Conference 63 RGB # 63 Randomized Phase 63 huC# DM4 63 Oral Fingolimod 63 Vaccine Adjuvant 63 Breaking Clinical Trials 63 Clinical Trial Results 63 ASCO Breast Cancer 63 Vicriviroc 63 BRIM2 63 orally inhaled migraine 63 CIMZIA TM certolizumab pegol 63 Antiviral Activity 63 NASDAQ CXSP announced 63 AACR #nd Annual Meeting 63 Phase Ib study 63 BAL# [001] 63 crizotinib PF # 63 Alzheimer Disease ICAD 63 Phase 1a clinical 63 Hedgehog Pathway Inhibitor 63 Romidepsin 63 trastuzumab DM1 T DM1 63 CRLX# 63 Immunogenicity 63 Traficet EN 63 LymphoStat B 63 Quinamed 63 transthyretin TTR mediated amyloidosis 63 Connective Tissue Oncology 63 Preclinical Efficacy 63 Safinamide 63 Pediatric Academic Societies PAS 63 annual Transcatheter Cardiovascular 63 alvespimycin 63 Vitro Activity 63 th Annual Interscience 63 Therapeutics TCT scientific 63 Pooled Analysis 63 HCV Protease Inhibitor 63 AHA Scientific Sessions 63 Selective Cardiac Myosin 62 Deforolimus 62 Omacetaxine 62 pharmacokinetic PK study 62 Pivotal Phase III 62 neratinib 62 selective androgen receptor modulator 62 AACR symposium 62 abstracts summarizing 62 Nasdaq ENZN 62 Nasdaq NYMX 62 Diabetic Macular Edema DME 62 Presents Preclinical Data 62 Pharmacodynamic 62 Carfilzomib 62 viral kinetics 62 Phase 1b clinical 62 Thiovir 62 PDX pralatrexate 62 Phase 2a clinical 62 RECORD1 62 IL# PE#QQR 62 HCV SPRINT 62 sorafenib tablets 62 Presents Preclinical 62 Phase #/#a 62 Selective Cardiac Myosin Activator 62 EXPAREL ™ 62 HCV NS5B polymerase 62 novel histone deacetylase 62 evaluating REVLIMID 62 histone deacetylase HDAC inhibitor 62 ACR ARHP 62 Radezolid 62 pan HDAC inhibitor 62 Phase Ib II 62 CYT# potent vascular disrupting 62 AVE# 62 PROSTVAC TM 62 vascular disrupting agent 62 League Against Rheumatism 62 PEG SN# 62 Denufosol 62 oral FTY# 62 Phase 2b Clinical Trial 62 Phase III AFFIRM 62 investigational protease inhibitor 62 BCX# 62 HCV Genotype 62 vidofludimus 62 phase IIb study 62 relapsed MM 62 NASDAQ AVNR 62 Phase 2a Study 62 Epratuzumab 61 recurrent glioma 61 HuMax EGFr 61 Phase IIa clinical 61 Presents Positive 61 Pharmacokinetic 61 liposomal formulation 61 ganetespib 61 Hematology ASH 61 ARVO 61 Pyridorin 61 AA Amyloidosis 61 elotuzumab 61 Double Blind Placebo 61 phase IIa clinical 61 AVERROES 61 interferon gamma 1b 61 trastuzumab emtansine T DM1 61 Study Evaluating 61 randomized discontinuation trial 61 Dalbavancin 61 San Antonio Breast Cancer 61 EGS# 61 phase IIb clinical 61 Novel Oral 61 Randomized Double Blind Placebo 61 forodesine 61 Pediatric Academic Societies 61 II Clinical Trial 61 ToGA 61 ZFP Therapeutic 61 ORENCIA ® 61 Pharmacokinetics PK 61 Enzastaurin 61 HCV RESPOND 2 61 Nasdaq GENR 61 mapatumumab 61 Aflibercept 61 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 61 Tezampanel 61 OHR/AVR# 61 Fifth Decennial International 61 DDW ® 61 Teriflunomide 61 Prostate AdenoCarcinoma Treatment 61 Tarceva TM 61 Sipuleucel T 61 Potent Antiviral Activity 61 Scientific Sessions 61 selective modulator 61 Nasdaq SGMO announced 61 preclinical pharmacokinetic 61 pharmacokinetic PK 61 Blinatumomab 61 ASBMR 61 MERIT ES 61 metaglidasen 61 Completes Patient Enrollment 61 RNAi Therapeutic 61 metastatic castration resistant 61 Androxal TM 61 Dapagliflozin 61 bazedoxifene conjugated estrogens 61 solithromycin 61 Zenvia Phase III 61 Phase III ALLEGRO 61 bicifadine 61 JAK inhibitor 61 NXL# 61 PSN# [002] 61 YONDELIS 61 phase IIa 61 INCB# [001] 61 alfa 2a 61 Inc. Nasdaq AVRX 61 Inc. Nasdaq IMGN 61 multicenter Phase II 60 #st Annual Meeting 60 Hematology Meeting 60 dual endothelin receptor antagonist 60 IMPACT DCM 60 Nasdaq IDRA today 60 Elagolix 60 OTCBB AOLS announced 60 Brentuximab Vedotin SGN 60 Solorel TM 60 Ambrisentan 60 PEGylated interferon beta 1a 60 QLT# 60 PNP inhibitor 60 FOLFOX6 chemotherapy regimen 60 Aplidin R 60 nucleotide analog 60 Tanespimycin 60 ceftazidime 60 CD# CEA 60 SPRYCEL ® 60 DASISION 60 Squalamine 60 MAP# 60 BOLDER II 60 ExTRACT TIMI 60 refractory chronic lymphocytic 60 Phase #b/#a clinical 60 Scientific Session 60 novel VDA molecule 60 CAMMS# 60 PRNewswire FirstCall Amylin Pharmaceuticals 60 Vascular Biology ATVB 60 Severe Sepsis 60 Phase 2a Trial 60 BAL# [002] 60 Cardiotoxicity 60 USpella 60 GLYX 60 Clinical Oncology Gastrointestinal Cancers 60 targeting CD# 60 multicenter randomized placebo controlled 60 Diabetic Macular Edema 60 PRNewswire FirstCall Genta Incorporated 60 cobiprostone 60 PROactive Study 60 Randomized Double blind 60 clevidipine 60 PRNewswire FirstCall Genaera 60 miconazole Lauriad ® 60 DermaVir Patch 60 CCX# 60 Boceprevir 60 brivanib 60 erlotinib Tarceva ® 60 EVEREST II 60 Cimzia ® certolizumab pegol 60 midstage clinical 60 desvenlafaxine succinate 60 SNT-MC#/idebenone 60 Inc. Nasdaq AMLN 60 proteasome inhibitor 60 Announces Poster Presentations 60 Endocrine Society Annual Meeting 60 Valopicitabine 60 investigational humanized monoclonal antibody 60 Therapeutic Competitors companiesandmarkets.com adEgemonye 60 riociguat 60 AACR IASLC Joint 60 Mipomersen 60 Intervention Effectiveness 60 ALN TTR 60 intranasal formulation 60 AACR NCI EORTC Molecular 60 HQK 60 Elvitegravir 60 MEND CABG 60 HORIZONS AMI 60 AEZS 60 Metastatic Melanoma 60 dose escalation clinical 60 FDA APPROVES 60 CTAP# Capsules 60 R roscovitine 60 Ophena TM 60 ASCO abstract 60 EORTC NCI 60 SAR# [004] 60 Pirfenidone 60 compound AEZS 60 Personalized Immunotherapy 60 davunetide intranasal AL 60 Belimumab 60 JAK2 Inhibitor 60 Solazed TM 60 Phase 2a trial 60 TMC# C# 60 entinostat 60 catheter occlusion 60 UEGW 60 galiximab 60 investigational hepatitis C 60 Aggressive Reduction 60 Triapine R 60 AEGR 60 NASDAQ ARRY 60 Achieves Primary Endpoint 60 Long Term Efficacy 60 tolerability profiles 60 AS# amonafide L malate 60 pomalidomide 60 EXPAREL TM 60 Pafuramidine 60 TRX1 60 Dasatinib 60 th Interscience Conference 60 evaluating mipomersen 60 ® pioglitazone HCl 60 HyQ 60 Immunotherapeutic 60 Demonstrates Efficacy 60 NASDAQ ISTA 59 SCH # 59 cetuximab Erbitux 59 Breast Cancer Symposium 59 pertuzumab 59 antiangiogenic activity 59 GAMMAGARD 59 selective kinase inhibitor 59 investigational monoclonal antibody 59 Nephrology Renal Week 59 phase IIb trial 59 XL# SAR# 59 HDAC Inhibitors 59 phase IIb 59 CANCIDAS 59 Vitaxin 59 Pre RELAX AHF 59 Inflammatory Arthritis 59 Nasdaq GNTA 59 Prospective Multicenter 59 Azedra 59 Valsartan 59 Antiviral Therapy 59 RE LY trial 59 TLK# 59 velafermin 59 ECCO ESMO 59 verteporfin 59 Natalizumab 59 Molecular Medicine Tri 59 Meets Primary Endpoint 59 NASDAQ IDRA 59 Clinical Efficacy 59 ENDO 59 HGS ETR2 59 Lysosomal Disease Network 59 DDP# 59 INGN 59 Protease Inhibitor 59 Abstract Number 59 Trodusquemine 59 TASKi2 59 LibiGel ® 59 Nasdaq OPTR 59 Kinase Inhibitor 59 registrational Phase 59 Prolongs Survival 59 CYC# 59 Inc. NASDAQ HEPH 59 viral kinetic 59 Romiplostim 59 multicenter multinational 59 HGS ETR1 59 Moxifloxacin 59 perifosine KRX 59 Medical Oncology ESMO 59 Pharmacokinetic PK 59 acute PAO 59 Genta Incorporated OTCBB GETA 59 Hormone Refractory Prostate Cancer 59 EULAR Annual 59 Plicera 59 lexidronam injection 59 thetreatment 59 BR.# 59 eltrombopag 59 systemic RNAi therapeutic 59 Breast Cancer Symposium SABCS 59 LAF# 59 Cethromycin 59 HuMax CD4 59 Naive Patients 59 assessing T DM1 59 ZD# [001] 59 prostate cancer mCRPC 59 Phase III ADT 59 Prostate Cancer Symposium 59 Dendritic Cells 59 Phase 2b Trial 59 Nasdaq REGN 59 PKC# 59 Tarvacin TM 59 VP# [004] 59 administered subcutaneously 59 GOUT 59 Phase Ib IIa 59 Phase 2b Study 59 Tolvaptan 59 LBH# 59 Hepatitis C HCV 59 ThermoDox ® clinical 59 Patients Treated With 59 REYATAZ R 59 Relapsing Multiple Sclerosis 59 Diabetic Neuropathy 59 hepatitis C HCV 59 Sangamo BioSciences Announces 59 Chicago Multidisciplinary Symposium 59 fidaxomicin Phase 3 59 ritonavir boosted 59 oral rivaroxaban 59 fidaxomicin Phase 59 vapreotide acetate 59 Phase 2a 59 investigational pan BCR 59 Inc. Nasdaq INFI 59 nonclinical studies 59 CR# vcMMAE 59 darinaparsin ZIO 59 telomerase inhibitor drug 59 demonstrated antitumor activity 59 CRMD# 59 evaluating Vectibix 59 oral proteasome inhibitor 59 Inc. Nasdaq BNVI 59 NASDAQ SLXP today 59 aclidinium 59 Chronic Hepatitis C 59 Phase IIb Trial 59 Annual Transcatheter Cardiovascular 59 number NCT# ClinicalTrials.gov 59 Bazedoxifene 59 Solid Tumors 59 Nasdaq PCYC 59 ATL/TV# 59 Tumor Response 59 Oral Presentations 59 Placebo Controlled Trial 59 PRT# 59 Cytokinetics Incorporated NASDAQ CYTK 59 phase 2a 59 plus Copegus R 59 ASCO Gastrointestinal Cancers Symposium 59 OXi# 59 prokinetic agent 59 See CLINICAL PHARMACOLOGY 59 NVA# 59 Poster Presentations 59 prospective multicentre 59 vivo efficacy 59 Initiate Phase 59 panitumumab Vectibix 59 Curaxin CBLC# 59 Golimumab 59 Triolex 59 Xcytrin R 59 Poster Discussion 59 investigational oral inhibitor 59 Phase IIIb clinical 59 HDAC Inhibitor 59 Systemic Sclerosis 59 EPIVIR 59 iclaprim 59 MT# MEDI 59 Investigational Treatment 59 visilizumab 59 Demonstrates Positive 59 Immunology Annual Meeting 59 TLR antagonists 59 MERLIN TIMI 59 Glatiramer Acetate 59 chills fever headache 58 Digestive Diseases Week 58 Drugs Affecting Lipid 58 AIR2 Trial 58 MBRX 58 Valortim R 58 S/GSK# 58 CALGB # [002] 58 mGluR5 negative 58 Tolerability 58 lumiliximab 58 PRTX 58 maximally tolerated dose 58 brand ciclesonide HFA 58 Prospective Randomized Trial 58 mertansine 58 Adefovir 58 rALLy clinical trial 58 Phase III placebo controlled 58 HCV polymerase inhibitors 58 Candesartan 58 SUCCEED trial 58 brivaracetam 58 mGluR5 NAM 58 novel defensin mimetic 58 Velcade bortezomib 58 Inc. Nasdaq VRUS 58 Amgen Neulasta R 58 ImmunoVEX HSV2 58 Microplasmin 58 Daclizumab 58 Gleevec imatinib mesylate 58 Newly Diagnosed Multiple Myeloma 58 Phase #/#a trial 58 GW# [003] 58 Initiates Enrollment 58 NEUVENGE 58 Heterozygous Familial Hypercholesterolemia 58 Phase IIIb 58 gastrointestinal stromal tumors GIST 58 humanized anti 58 Phase 1b 58 NovaBay Aganocide compounds 58 Hematological Malignancies 58 Vaccine Immunology 58 Mg Usa 58 Inc. Nasdaq BIOD 58 Decitabine 58 pralatrexate injection folate analogue 58 Endovascular Valve Edge 58 Cloretazine R 58 Initiated Phase 58 TRANSFORMS 58 anti amnesic 58 Trofex TM 58 PreCISe 58 mitogen activated ERK kinase 58 romidepsin 58 guanfacine extended release 58 orally bioavailable 58 ENMD # 58 recurrent malignant glioma 58 Nasdaq ONXX today 58 phase Ib 58 Talabostat 58 AAG geldanamycin analog 58 Poster Session 58 TAXUS ATLAS 58 Inhalation Solution 58 Mg Uk 58 ADVANCE PD 58 INCB# [003] 58 NEUGENE 58 Myelodysplastic Syndrome MDS 58 Cancer Cachexia 58 Abstract Accepted 58 INSPIRE Trial Phase III 58 polymerase inhibitor 58 PSMA ADC 58 diabetic neuropathic pain 58 APOPTONE 58 Temsirolimus 58 Ampligen ® 58 Reolysin 58 AUA Annual Meeting 58 Aganocide 58 glucocorticoid induced osteoporosis 58 Reports Preclinical Data 58 RhuDex ® 58 LEVADEX ™ 58 Treatment Naïve 58 AVN# Phase 58 TELINTRA 58 GRNCM1 58 Acute Ischemic Stroke 58 aclidinium bromide 58 ocular formulation 58 oral methylnaltrexone 58 BiTE antibody MT# 58 plasma kallikrein inhibitor 58 Xanafide 58 nitazoxanide 58 recurrent glioblastoma multiforme 58 Targeted Anticancer Therapies 58 non nucleoside HCV 58 EOquin TM 58 BiTE ® 58 Transcatheter Cardiovascular Therapeutics 58 HCV protease inhibitors 58 Sym# 58 protein kinase inhibitor 58 Interferon beta 1b 58 MAGE A3 ASCI 58 Cachexia 58 Sanofi aventis EURONEXT SAN 58 virus HBV 58 www.asco.org 58 Exelixis compounds 58 antiviral activity 58 AZT zidovudine Retrovir 58 NS5b 58 cannabinor 58 HIF PHI 58 trastuzumab Herceptin R 58 Mycophenolate Mofetil 58 Seliciclib 58 PROSTASCINT R 58 Oral Presentation 58 Prospective Randomized 58 hemagglutination inhibition HAI 58 Alocrest 58 BRAF inhibitor 58 toenail onychomycosis 58 Tyrosine Kinase Inhibitor 58 Chemophase 58 SNT MC# 58 CEQ# 58 Inc. Nasdaq OPTR 58 alpha antagonist 58 Malignant Lymphoma 58 BIOCOM Investor Conference 58 standard chemotherapy regimen 58 Varespladib 58 abacavir Ziagen 58 LT NS# 58 investigational antiplatelet 58 PCK# 58 Nasdaq SNSS 58 randomized Phase III 58 R lenalidomide 58 Kahalalide F 58 Endocrine Society #nd 58 Initiates Clinical Trial 58 Acute Heart Failure 58 DAVANAT 58 Phase 1b clinical trials 58 Advanced Renal Cell 58 Fingolimod 58 SPL# Gel vaginal microbicide 58 OncoVEX GM CSF 58 Aplidin 58 Panzem R 58 placebo controlled clinical 58 ASGT 58 JAK2 inhibitor 58 Archexin 58 sodium thiosulfate STS 58 Fondaparinux 58 Therapeutics Roundtable 58 HCV protease inhibitor 58 Antitumor Activity 58 Orally Active 58 Tesetaxel 57 Drug Candidate 57 phase IIIb 57 reslizumab 57 antiviral efficacy 57 Therapeutics TCT 57 PROVENGE sipuleucel T 57 immunomodulator 57 receptor inhibitor 57 adipiplon 57 Benign Prostatic Hyperplasia 57 Tyrima 57 Urocortin 2 57 Randomized Double Blind 57 ISTODAX ® 57 multi kinase inhibitor 57 Trandolapril 57 Bioral ® 57 Shows Efficacy 57 CCR5 antagonist 57 cediranib 57 DU #b 57 Oral NKTR 57 Zoraxel 57 Clinical Trial Data 57 Hematologic 57 Multimeric 57 RE SURGE 57 GASTRO 57 tasocitinib 57 Telaprevir VX 57 Heart Failure Society 57 Zenvia ™ 57 Guanilib 57 Serious Infections 57 GVAX ® 57 Glufosfamide 57 Well Tolerated 57 novel trazodone formulation 57 PS# [001] 57 AAO HNSF Annual Meeting 57 worsening thrombocytopenia 57 volociximab 57 pentostatin 57 Nexavar sorafenib 57 ARIKACE 57 isoform selective 57 Dacogen injection 57 Zarnestra 57 p# inhibitor 57 Relapsed Multiple Myeloma 57 BIO InvestorForum 57 Silodosin 57 LENALIDOMIDE 57 RoACTEMRA 57 cMET 57 NIH Consensus 57 Activator CK # 57 ALN TTR# 57 seliciclib CYC# 57 SU# [003] 57 Pharmacokinetic parameters 57 plus Copegus 57 Tiotropium 57 Ocrelizumab 57 Phase 2a Clinical Trial 57 Amrubicin 57 Genta Incorporated OTCBB 57 sorafenib Nexavar 57 IRX 2 57 Advanced Neuroendocrine Tumors 57 Bucindolol 57 CLARITY study 57 Dose Escalation 57 Anti Tumor 57 posaconazole 57 Fulvestrant 57 Altastaph 57 Tß4 57 ENDEAVOR III 57 generation purine nucleoside 57 oral ridaforolimus 57 SinuNase TM 57 J.P. Morgan Healthcare 57 orally dosed 57 NP2 Enkephalin 57 TG MV 57 Opportunistic Infections 57 depsipeptide 57 TMC# [002] 57 recurrent genital herpes 57 European CanCer Organisation ECCO 57 Complicated Skin 57 MYTHOS trial 57 huN# DM1 57 CLARITY TIMI 57 telomerase therapeutic 57 MT#/MEDI-# 57 Phase III psoriasis 57 Molecular Cancer 57 Aurora Kinase 57 Controlled Trial 57 protease inhibitor PI 57 Endocrine Society #st 57 phase IIb III 57 PD LID 57 America HFSA 57 systemically administered 57 EDEMA3 trial 57 laquinimod 57 Transdermal Patch 57 Lisofylline 57 retaspimycin 57 GTCbio 3rd 57 oxidative stress inducer 57 plasma pharmacokinetics 57 Liver Diseases AASLD 57 AACR Frontiers 57 Bezielle 57 Active Ulcerative Colitis 57 Perifosine 57 immunomodulatory 57 Annamycin 57 candesartan cilexetil 57 Bortezomib 57 metastatic malignant 57 UPLYSO 57 tolvaptan 57 brand eszopiclone 57 TÎ ² 4 57 rasagiline tablets 57 Pharmacodynamics 57 Pemphigus Vulgaris 57 Femara letrozole 57 Melanoma Skin Cancers 57 Active Biotech NASDAQ OMX 57 tipifarnib 57 Xelox 57 Platelet Inhibition 57 RNA interference RNAi therapeutics 57 Nasdaq EMIS 57 NYSE Alternext ULU 57 Liver EASL 57 colesevelam HCl 57 AABB Annual Meeting 57 & Immunology AAAAI 57 humanized interleukin 6 57 NASDAQ INHX 57 histone deacetylase inhibitor 57 trodusquemine 57 Phase #b/#a trial 57 dose escalation trial 57 ATACAND 57 dasatinib Sprycel 57 Tipranavir 57 Virulizin ® 57 HIF PH inhibitors 57 PXD# 57 CYT# 57 vinca alkaloid 57 essential thrombocythemia ET 57 SYN# 57 antibody MT# 57 IDX# 57 rNAPc2 57 AMD# [002] 57 NEUGENE R 57 Monotherapy 57 Vaccine Protects Against 57 EGFR HER2 57 AKT inhibitor 57 Factor VIIa 57 placebo controlled Phase III 57 multicenter Phase 57 CIMZIA ™ 57 Pegylated Interferon 57 complement inhibitor eculizumab 57 inhibitor RG# 57 Lenocta 57 VivaGel ™ 57 ANCHOR trial 57 preclinical pharmacology 57 REG2 57 FASLODEX 57 ADAGIO study 57 Phase III Clinical Trial 57 AZILECT 57 Laquinimod 57 IMiDs R 57 deforolimus 57 Neurology AAN 57 R#/MEM # 57 OMP #M# 57 investigational compounds 57 decitabine 57 varespladib 57 PEG Interferon lambda 57 AACR Annual Meeting 57 extrapulmonary disease 57 orally administered inhibitor 57 oxymorphone ER 57 Randomized Phase II 57 nucleoside analog 57 Onbrez Breezhaler 57 omacetaxine mepesuccinate 57 Apoptone 57 Tracleer R 57 Nasdaq IMGN 57 Pazopanib 57 VA# [002] 57 Safety Tolerability 57 LY# [003] 57 Anticancer Drugs 57 MLN# 57 Pulmonary Arterial Hypertension 57 cyclophilin inhibitors 57 lomitapide 57 isatoribine 57 relapsed multiple myeloma 57 small molecule defensin 57 AZILECT R 57 retinal vein occlusion induced 57 Acute Myocardial Infarction 57 Phase IIa trial 57 Endocrine Society ENDO 57 Adentri 57 #I TM# 57 Annual Interscience Conference 57 Inc. NASDAQ AGIX 57 antifibrotic 57 Interferon beta 1a 57 Inc. Nasdaq SEPR 57 axitinib 57 DXL# 57 TO AVOID PREGNANCY WHILE 57 Cambridge Healthtech Institute 57 MGd 57 novel peptide 56 Sprycel dasatinib 56 pharmacodynamic properties 56 Treatment Experienced 56 XL# XL# 56 pediatric acute lymphoblastic 56 antibody blinatumomab MT#/MEDI-# 56 Single Dose 56 Nanobody 56 Viprovex TM 56 immune modulatory 56 CYP#A# CYP#D# 56 Phase 2b clinical 56 Removab 56 CTRC AACR 56 entecavir 56 Patients Receiving 56 Outpatient Setting 56 IAP inhibitors 56 TORISEL TM 56 cathepsin K inhibitor 56 Nordic ACTI 56 Inc. OTCBB LPTN 56 IL #E 56 oncolytic virus therapies 56 LAB CGRP 56 Proc Am Soc 56 PRNewswire FirstCall Tercica 56 Podium Presentation 56 First Patient Enrolled 56 USL# 56 xanthine oxidase inhibitor 56 Valortim ® 56 rosuvastatin Crestor 56 HCV protease 56 Neurology Annual Meeting 56 oral antiviral 56 S#.# [006] 56 trial evaluating PRX# 56 dacetuzumab 56 TransVax ™ 56 Targanta Therapeutics Corporation 56 psoriatic arthritis PsA 56 enzastaurin 56 Nasdaq NPSP 56 highly selective inhibitor 56 Novel Antibiotic 56 AVOREN 56 Demonstrates Sustained 56 milatuzumab 56 Reverset 56 Progressive Multifocal Leukoencephalopathy 56 Gemzar ® 56 Nasdaq ALXN 56 Phase IIa Clinical Trial 56 Chronic Lymphocytic Leukemia

Back to home page